All In Biotech

Drug Trial Radar · NCT03344159

Spironolactone Therapy in Chronic Stable Right HF Trial

Last checked: Nov 21, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Apr 1, 2018

Primary completion

Aug 30, 2022

Study completion May 1, 2024

Sponsor

Lead sponsor
Ottawa Heart Institute Research CorporationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in patients with chronic right heart failure.

Conditions

  • Chronic Right-Sided Heart Failure
  • Pulmonary Arterial Hypertension
  • Pulmonary Hypertension, Primary, 2
  • Pulmonary Hypertension, Primary, 3
  • Pulmonary Hypertension, Primary, 4
  • Cardiomyopathy Right Ventricular

Interventions

  • SpironolactoneDrug

    Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.

  • PlaceboDrug

    Placebo daily for a total of duration of 12 weeks

  • PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82Radiation

    At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.

  • Cardiac MRI (Gadolinium enhanced)Diagnostic test

    At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Ventricular Wall StressTime frame: Baseline and 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.